Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New issues in oral anticoagulants.

Hematology. American Society of Hematology. Education Program - 1 Jan 2008

Francis Charles W

Abstract excerpt

Polymorphisms in CYP2C9, a critical cytochrome P-450 enzyme in the metabolism of warfarin, alters its clearance and affects dosing. CYP*1 has higher activity than either the *2 or *3 variants, and patients with the *2 or *3 variants require a lower dose. VKORC1 is the enzyme inhibited by warfarin, and its levels are affected by several polymorphisms that can be divided into high or low level haplotypes, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Anticoagulants
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Morpholines

Share to Thiophenes

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Identifiers

PMID: 19074093
DOI: 10.1182/asheducation-2008.1.259

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New issues in oral anticoagulants.PMID 19074093Read ↗

Role of pharmacogenomics in the management of traditional and novel oral anticoagulants.Semantic proximity Read ↗

Pharmacogenetics of Novel Oral Anticoagulants: A Review of Identified Gene Variants & Future PerspectivesSemantic proximity Read ↗

Oral anticoagulation: a critique of recent advances and controversies.Semantic proximity Read ↗

PHARMACOGENOMICS OF NOVEL ORAL ANTICOAGULANTS (NOACs): CURRENT INSIGHTS AND FUTURE DIRECTIONSSemantic proximity Read ↗

Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic VariantsSemantic proximity Read ↗

New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics?Semantic proximity Read ↗

Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?Semantic proximity Read ↗

Effect of ABCB1 Genotypes on the Pharmacokinetics and Clinical Outcomes of New Oral Anticoagulants: A Systematic Review and Meta-analysisSemantic proximity Read ↗

Risk Factors for Rivaroxaban-Related Bleeding Events—Possible Role of Pharmacogenetics: Case SeriesSemantic proximity Read ↗

Current challenges in personalizing warfarin therapy.Semantic proximity Read ↗

Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement SurgerySemantic proximity Read ↗

Pharmacogenetics of Bleeding and Thromboembolic Events in Direct Oral Anticoagulant Users.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.